Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Handling of hemolyzed serum samples in clinical chemistry laboratories: the Nordic hemolysis project.

Gidske G, Aakre KM, Rustad P, Sandberg S, Norling A, Pelanti J, Henriksen G, Thorsteinsdottir I, Kristensen GBB.

Clin Chem Lab Med. 2019 Oct 25;57(11):1699-1711. doi: 10.1515/cclm-2019-0366.

PMID:
31617690
2.

European survey on preanalytical sample handling - Part 2: Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).

Cadamuro J, Lippi G, von Meyer A, Ibarz M, van Dongen E; Lases5, Cornes M, Nybo M, Vermeersch P, Grankvist K, Guimaraes JT, Kristensen GBB, de la Salle B, Simundic AM.

Biochem Med (Zagreb). 2019 Jun 15;29(2):020705. doi: 10.11613/BM.2019.020705.

3.

European survey on preanalytical sample handling - Part 1: How do European laboratories monitor the preanalytical phase? On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).

Cadamuro J, Lippi G, von Meyer A, Ibarz M, van Dongen E; Lases5, Cornes M, Nybo M, Vermeersch P, Grankvist K, Guimaraes JT, Kristensen GBB, de la Salle B, Simundic AM.

Biochem Med (Zagreb). 2019 Jun 15;29(2):020704. doi: 10.11613/BM.2019.020704.

4.

Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM).

Kristoffersen AH, Stavelin AV, Ajzner E, Kristensen GBB, Sandberg S, Van Blerk M, Kitchen S, Kesseler D, Woods TAL, Meijer P.

Clin Chem Lab Med. 2019 Sep 25;57(10):1511-1521. doi: 10.1515/cclm-2019-0214.

PMID:
31085743
5.

Joint EFLM-COLABIOCLI recommendation for venous blood sampling.

Simundic AM, Bölenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P.

Ann Biol Clin (Paris). 2019 Apr 1;77(2):131-154. doi: 10.1684/abc.2019.1419. Review.

PMID:
30998194
6.

Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer.

Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H.

Neoplasia. 2019 Apr;21(4):353-362. doi: 10.1016/j.neo.2019.01.002. Epub 2019 Mar 8.

7.

Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK.

Acta Oncol. 2019 Jun;58(6):828-837. doi: 10.1080/0284186X.2019.1580386. Epub 2019 Feb 27.

PMID:
30810443
8.

Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers.

Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H.

Transl Oncol. 2019 Mar;12(3):576-584. doi: 10.1016/j.tranon.2018.12.010. Epub 2019 Jan 17.

9.

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.

Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW.

Clin Cancer Res. 2019 Apr 1;25(7):2155-2165. doi: 10.1158/1078-0432.CCR-18-2792. Epub 2019 Jan 7.

PMID:
30617134
10.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators.

Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413383
11.

Status on fasting definition for blood sampling in the Nordic countries - time for a harmonized definition.

Grankvist K, Sigthorsson G, Kristensen GB, Pelanti J, Nybo M.

Scand J Clin Lab Invest. 2018 Nov - Dec;78(7-8):591-594. doi: 10.1080/00365513.2018.1528503. Epub 2018 Oct 19.

PMID:
30338721
12.

Joint EFLM-COLABIOCLI Recommendation for venous blood sampling

Simundic AM, Bölenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov H, Kovalevskaya S, Kristensen GBB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, De la Salle B, Seipelt C, Sumarac Z, Vermeersch P; Working Group for Preanalytical Phase (WG-PRE), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI).

Clin Chem Lab Med. 2018 Nov 27;56(12):2015-2038. doi: 10.1515/cclm-2018-0602. Review.

13.

DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma.

Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1193-1201. doi: 10.1016/j.ijrobp.2018.04.035. Epub 2018 Apr 19.

PMID:
29859790
14.

Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.

Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE.

J Natl Cancer Inst. 2018 Dec 1;110(12):1400-1408. doi: 10.1093/jnci/djy063.

15.

Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples.

Gidske G, Sølvik UØ, Sandberg S, Kristensen GBB.

Clin Chem Lab Med. 2018 Aug 28;56(9):e220-e222. doi: 10.1515/cclm-2018-0193. No abstract available.

PMID:
29630512
16.

Chromatin organisation and cancer prognosis: a pan-cancer study.

Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE.

Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3.

17.

[Properties of cancer cell DNA affects the prognosis].

Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE.

Tidsskr Nor Laegeforen. 2017 Oct 16;137(19). doi: 10.4045/tidsskr.16.0966. Print 2017 Oct 17. Review. Norwegian.

18.

A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway.

Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A.

Acta Obstet Gynecol Scand. 2017 Oct;96(10):1162-1169. doi: 10.1111/aogs.13199.

PMID:
28795770
19.

Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer.

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK.

Acta Oncol. 2017 May;56(5):675-681. doi: 10.1080/0284186X.2017.1294762. Epub 2017 Feb 28.

PMID:
28447564
20.

Interpretation of EQA results and EQA-based trouble shooting.

Kristensen GB, Meijer P.

Biochem Med (Zagreb). 2017 Feb 15;27(1):49-62. doi: 10.11613/BM.2017.007. Review.

21.

Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.

Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I.

Gynecol Oncol. 2017 Jun;145(3):543-548. doi: 10.1016/j.ygyno.2017.03.008. Epub 2017 Mar 27.

PMID:
28356187
23.

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC.

Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.

24.

Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients.

Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H.

PLoS One. 2016 May 31;11(5):e0156259. doi: 10.1371/journal.pone.0156259. eCollection 2016.

25.

Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.

Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM.

Am J Clin Pathol. 2016 Apr;145(4):449-58. doi: 10.1093/ajcp/aqw030.

PMID:
27149024
26.

The role of European Federation of Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase in standardization and harmonization of the preanalytical phase in Europe.

Cornes MP, Church S, van Dongen-Lases E, Grankvist K, Guimarães JT, Ibarz M, Kovalevskaya S, Kristensen GB, Lippi G, Nybo M, Sprongl L, Sumarac Z, Simundic AM; Working Group for Preanalytical Phase (WG-PRE) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Ann Clin Biochem. 2016 Sep;53(Pt 5):539-47. doi: 10.1177/0004563216643969. Epub 2016 May 1. Review.

PMID:
27141012
27.

Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.

Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H.

Clin Cancer Res. 2016 Aug 15;22(16):4067-76. doi: 10.1158/1078-0432.CCR-15-2322. Epub 2016 Mar 24.

28.

Patient identification and tube labelling - a call for harmonisation.

van Dongen-Lases EC, Cornes MP, Grankvist K, Ibarz M, Kristensen GB, Lippi G, Nybo M, Simundic AM; Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).

Clin Chem Lab Med. 2016 Jul 1;54(7):1141-5. doi: 10.1515/cclm-2015-1089.

29.

Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.

Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H.

Epigenetics. 2015;10(10):970-80. doi: 10.1080/15592294.2015.1085140.

30.

Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer.

Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK.

Radiother Oncol. 2015 Jun;115(3):379-85. doi: 10.1016/j.radonc.2015.05.001. Epub 2015 May 18.

PMID:
25998804
31.

Compliance of blood sampling procedures with the CLSI H3-A6 guidelines: An observational study by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PRE).

Simundic AM, Church S, Cornes MP, Grankvist K, Lippi G, Nybo M, Nikolac N, van Dongen-Lases E, Eker P, Kovalevskaya S, Kristensen GB, Sprongl L, Sumarac Z.

Clin Chem Lab Med. 2015 Aug;53(9):1321-31. doi: 10.1515/cclm-2014-1053.

32.

Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE).

Lippi G, Banfi G, Church S, Cornes M, De Carli G, Grankvist K, Kristensen GB, Ibarz M, Panteghini M, Plebani M, Nybo M, Smellie S, Zaninotto M, Simundic AM; European Federation for Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase.

Clin Chem Lab Med. 2015 Feb;53(3):357-70. doi: 10.1515/cclm-2014-1051.

33.

Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas.

Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE.

Cytometry A. 2015 Apr;87(4):315-25. doi: 10.1002/cyto.a.22601. Epub 2014 Dec 5.

34.

Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma.

Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK.

Radiother Oncol. 2014 Oct;113(1):132-8. doi: 10.1016/j.radonc.2014.09.011. Epub 2014 Oct 15.

PMID:
25443501
35.

Nursing home patients with diabetes: prevalence, drug treatment and glycemic control.

Andreassen LM, Sandberg S, Kristensen GB, Sølvik UØ, Kjome RL.

Diabetes Res Clin Pract. 2014 Jul;105(1):102-9. doi: 10.1016/j.diabres.2014.04.012. Epub 2014 Apr 28.

36.

How to conduct External Quality Assessment Schemes for the pre-analytical phase?

Kristensen GB, Aakre KM, Kristoffersen AH, Sandberg S.

Biochem Med (Zagreb). 2014 Feb 15;24(1):114-22. doi: 10.11613/BM.2014.013. eCollection 2014. Review.

37.

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).

Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B.

BMC Cancer. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68.

38.

Gene expression signatures of primary and metastatic uterine leiomyosarcoma.

Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL.

Hum Pathol. 2014 Apr;45(4):691-700. doi: 10.1016/j.humpath.2013.11.003. Epub 2013 Nov 13.

39.

Long-term outcomes after pelvic radiation for early-stage endometrial cancer.

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K.

J Clin Oncol. 2013 Nov 1;31(31):3951-6. doi: 10.1200/JCO.2013.48.8023. Epub 2013 Sep 9.

PMID:
24019546
40.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.

Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27.

PMID:
23994107
41.

High levels of genomic aberrations in serous ovarian cancers are associated with better survival.

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P; Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL.

PLoS One. 2013;8(1):e54356. doi: 10.1371/journal.pone.0054356. Epub 2013 Jan 23.

42.

Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling.

Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H.

J Pathol. 2013 May;230(1):59-69. doi: 10.1002/path.4168. Epub 2013 Mar 14.

PMID:
23335387
43.

Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.

Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E.

Radiother Oncol. 2013 Apr;107(1):117-22. doi: 10.1016/j.radonc.2012.11.007. Epub 2013 Jan 17.

PMID:
23333024
44.

Calcium, magnesium, albumin, and total protein measurement in serum as assessed with 20 fresh-frozen single-donation sera.

Van Houcke SK, Rustad P, Stepman HC, Kristensen GB, Stöckl D, Røraas TH, Sandberg S, Thienpont LM.

Clin Chem. 2012 Nov;58(11):1597-9. doi: 10.1373/clinchem.2012.189670. Epub 2012 Sep 5. No abstract available.

45.

Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI.

Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H.

Cancer Res. 2012 Oct 15;72(20):5285-95. doi: 10.1158/0008-5472.CAN-12-1085. Epub 2012 Aug 13.

46.

DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium.

Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ.

Virchows Arch. 2012 Sep;461(3):291-8. doi: 10.1007/s00428-012-1275-2. Epub 2012 Jul 24.

47.

Diagnosis and treatment of sarcoma of the uterus. A review.

Tropé CG, Abeler VM, Kristensen GB.

Acta Oncol. 2012 Jul;51(6):694-705. doi: 10.3109/0284186X.2012.689111. Review.

PMID:
22793037
48.

The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer.

Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, Danielsen HE.

Anal Cell Pathol (Amst). 2012;35(4):305-14. doi: 10.3233/ACP-2012-0065.

49.

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB.

Ann Oncol. 2012 Oct;23(10):2613-9. Epub 2012 Apr 26.

PMID:
22539562
50.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E.

Br J Cancer. 2012 May 22;106(11):1728-34. doi: 10.1038/bjc.2012.158. Epub 2012 Apr 24.

Supplemental Content

Loading ...
Support Center